MAY 12, 2020 8:43 PM PDT

Novel Drug Approved for Non-Small Cell Lung Cancer

WRITTEN BY: Nouran Amin

The US Food and Drug Administration (FDA) recently approved a therapeutic for treating metastatic non-small cell lung cancer (NSCLC). The therapeutic called ‘Tabrecta™ (capmatinib, formerly INC280)’ is an oral MET inhibitor for patients with a METex14 mutation in their tumors.

Learn more about non-small cell lung cancer (NSCLC):

 

 

“Non-small cell lung cancer is a complex disease, with many different possible mutations that may encourage the cancer’s growth,” said Juergen Wolf, MD, from the Center for Integrated Oncology, University Hospital Cologne and lead investigator of the GEOMETRY study. “MET exon 14 skipping is a known oncogenic driver. With today’s decision by the FDA, we can now test for and treat this challenging form of lung cancer with targeted therapy, offering new hope for patients with NSCLC harboring this type of mutation.”

The approval of Trabecta is based on findings from the pivotal GEOMETRY mono-1 Phase II clinical trial. The most common side-effects noted were peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite.

“Today, and especially during these difficult times, we are incredibly proud that Tabrecta is the first treatment approved by the FDA specifically to treat patients diagnosed with this aggressive NSCLC associated with METex14,” said Susanne Schaffert, PhD, President, Novartis Oncology. “In our quest to reimagine medicine, we have worked tirelessly over the past decades to advance the understanding and treatment of NSCLC, striving to make a difference in patients’ lives, one mutation at a time. We thank all the physicians, patients and families involved in the Tabrecta clinical trials, and we remain committed to advancing innovative solutions for the patients we work to serve.”

Source: Novartis

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
MAY 26, 2020
Drug Discovery & Development
Everyone Can Produce Antibodies Against COVID-19
MAY 26, 2020
Everyone Can Produce Antibodies Against COVID-19
Researchers at Rockefeller University in New York have found that most people exposed to COVID-19, and who experience sy ...
MAY 26, 2020
Drug Discovery & Development
Eliminating Drug Side-Effects
MAY 26, 2020
Eliminating Drug Side-Effects
Can we live in a world that completely eliminates side-effects from therapeutics? Well, scientists from Hong Kong Baptis ...
MAY 28, 2020
Cancer
The Oncogenic Hazard of a Potential Alzheimer's Treatment
MAY 28, 2020
The Oncogenic Hazard of a Potential Alzheimer's Treatment
Breast cancer remains one of the most common cancers around the world. Triple-Negative Breast Cancer (TNBC) is a sub-typ ...
JUN 04, 2020
Cancer
Inhibiting the Signals Critical for Cancer Growth in Merkel Cell Carcinoma
JUN 04, 2020
Inhibiting the Signals Critical for Cancer Growth in Merkel Cell Carcinoma
Merkel Cell Carcinoma (MCC) is a highly aggressive cancer of the skin. It is characterized by a high recurrence rate and ...
JUN 10, 2020
Drug Discovery & Development
A Highly Targeted Cancer Therapeutic
JUN 10, 2020
A Highly Targeted Cancer Therapeutic
A study led by researchers at USC School of Pharmacy discusses a way to engineer drugs that highly target malignant tiss ...
JUL 08, 2020
Cancer
Tracking Down Biomarkers for Bladder Cancer Using Mass Spectrometry
JUL 08, 2020
Tracking Down Biomarkers for Bladder Cancer Using Mass Spectrometry
Bladder cancer is one of the most common cancers in the world. Non-muscle invasive bladder cancer (NMIBC) is a precursor ...
Loading Comments...